Aktis Oncology
Last verified 2026-05-05. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $175.0Mattributed |
|---|---|
| Latest round | series-b, $175.0M, 2024-09-01attributed |
| Founded | 2020 |
| Headquarters | Boston MA |
| Industry | biotech|oncology|radiopharmaceuticals |
| Stage | series-b+ |
| Website | aktisoncology.com |
Aktis Oncology develops targeted alpha-emitter radiopharmaceuticals using a proprietary miniprotein radioconjugate platform. It serves cancer patients with tumor types previously out of reach of radioligand therapies. Differentiator: miniprotein scaffolds aim to expand the radiopharmaceutical-treatable patient population.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-09-01 | series-b | $175.0M | undisclosed |
Detected tech stack
Nginx, WordPress, MailChimp for WordPress 4.12.5, Yoast SEO 27.6, Genesis theme, Google Analytics, Google Tag Manager, Sassy Social Share 3.3.79, PHP, DoubleClick Floodlight, Contact Form 7 6.1.6, WP Engine
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series B, $175.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $175.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | aktisoncology.com, read 2026-05-05 |
| Description | self-reported | aktisoncology.com, read 2026-05-05 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.